Disciplined approach to drug discovery and early development

Science Translational Medicine

Volumn 8, Issue 349, 2016, Pages

  Plenge, Robert M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

ARTICLE; AUTOIMMUNITY; BACTERIAL INFECTION; BIOLOGICAL ACTIVITY; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; HEALTH CARE SYSTEM; HUMAN; HUMAN GENETICS; NEXT GENERATION SEQUENCING; NONHUMAN; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHYSIOLOGY; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM; TRANSLATIONAL RESEARCH; VIRUS INFECTION; DRUG DESIGN; THEORETICAL MODEL;

DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, THEORETICAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84980000131     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf2608     Document Type: Article

References (30)

1. J. W. Scannell, A. Blanckley, H. Boldon, B. Warrington, Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200 (2012).
2. A. Mullard, 2015 FDA drug approvals. Nat. Rev. Drug Discov. 15, 73-76 (2016).
3. J. A. DiMasi, H. G. Grabowski, R. W. Hansen, Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 47, 20-33 (2016).
4. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, A. L. Schacht, How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
5. I. Kola, J. Landis, Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
6. M. J. Waring, J. Arrowsmith, A. R. Leach, P. D. Leeson, S. Mandrell, R. M. Owen, G. Pairaudeau, W. D. Pennie, S. D. Pickett, J. Wang, O. Wallace, A. Weir, An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475-486 (2015).
7. M. Hay, D. W. Thomas, J. L. Craighead, C. Economides, J. Rosenthal, Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51 (2014).
8. J. W. Scannell, J. Bosley, When quality beats quantity: Decision theory, drug discovery, and the reproducibility crisis. PLOS One 11, e0147215 (2016).
9. M. R. Nelson, H. Tipney, J. L. Painter, J. Shen, P. Nicoletti, Y. Shen, A. Floratos, P. Chung Sham, M. Jun Li, J. Wang, L. R. Cardon, J. C. Whittaker, P. Sanseau, The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856-860 (2015).
10. D. Cook, D. Brown, R. Alexander, R. March, P. Morgan, G. Satterthwaite, M. N. Pangalos, Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431 (2014).
11. P. Morgan, P. H. Van Der Graaf, J. Arrowsmith, D. E. Feltner, K. S. Drummond, C. D. Wegner, S. D. A. Street, Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419-424 (2012).
12. P. K. Owens, E. Raddad, J. W. Miller, J. R. Stille, K. G. Olovich, N. V. Smith, R. S. Jones, J. C. Scherer, A decade of innovation in pharmaceutical R&D: The chorus model. Nat. Rev. Drug Discov. 14, 17-28 (2015).
13. U. Schulze, M. Baedeker, Y. T. Chen, D. Greber, R&D productivity: On the comeback trail. Nat. Rev. Drug Discov. 13, 331-332 (2014).
14. https://www2.deloitte.com/content/dam/Deloitte/uk/ Documents/life-sciences-health-care/uk-deloitte-lshcpharma- innovation-2015.pdf.
15. R. M. Plenge, E. M. Scolnick, D. Altshuler, Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581-594 (2013).
16. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Biological insights from 108 schizophreniaassociated genetic loci. Nature 511, 421-427 (2014).
17. R. C. Dale, V. Merheb, S. Pillai, D.Wang, L. Cantrill, T. K. Murphy, H. Ben-Pazi, S. Varadkar, T. D. Aumann,M. K. Horne, A. J. Church, T. Fath, F. Brilot, Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 135, 3453-3468 (2012).
18. V. M. Narasimhan, K. A. Hunt, D. Mason, C. L. Baker, K. J. Karczewski, M. R. Barnes, A. H. Barnett, C. Bates, S. Bellary, N. A. Bockett, K. Giorda, C. J. Griffiths, H. Hemingway, Z. Jia, M. Ann Kelly, H. A. Khawaja, M. Lek, S. McCarthy, R. McEachan, A. O'Donnell-Luria, K. Paigen, C. A. Parisinos, E. Sheridan, L. Southgate, L. Tee, M. Thomas, Y. Xue, M. Schnall-Levin, P. M. Petkov, C. Tyler-Smith, E. R. Maher, R. C. Trembath, D. G. MacArthur, J. Wright, R. Durbin, D. A. van Heel, Health and population effects of rare gene knockouts in adult humans with related parents. Science 352, 474-477 (2016).
19. D. Corti, J. Voss, S. J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S. G. Vachieri, D. Pinna, A. Minola, F. Vanzetta, C. Silacci, B. M. Fernandez-Rodriguez, G. Agatic, S. Bianchi, I. Giacchetto-Sasselli, L. Calder, F. Sallusto, P. Collins, L. F. Haire, N. Temperton, J. P. M. Langedijk, J. J. Skehel, A. Lanzavecchia, A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
20. G. L. Verdine, L. D. Walensky, The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270 (2007).
21. S. Nishino, B. Ripley, S. Overeem, G. J. Lammers, E. Mignot, Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39-40 (2000).
22. M. Rask-Andersen, S. Masuram, H. B. Schiöth, The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9-26 (2014).
23. E. Sidransky, G. Lopez, The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986-998 (2012).
24. J. A. Howe, H. Wang, T. O. Fischmann, C. J. Balibar, L. Xiao, A. M. Galgoci, J. C. Malinverni, T. Mayhood, A. Villafania, A. Nahvi, N. Murgolo, C. M. Barbieri, P. A. Mann, D. Carr, E. Xia, P. Zuck, D. Riley, R. E. Painter, S. S. Walker, B. Sherborne, R. de Jesus, W. Pan, M. A. Plotkin, J. Wu, D. Rindgen, J. Cummings, C. G. Garlisi, R. Zhang, P. R. Sheth, C. J. Gill, H. Tang, T. Roemer, Selective small-molecule inhibition of an RNA structural element. Nature 526, 672-677 (2015).
25. R. J. Kleiman, M. D. Ehlers, Data gaps limit the translational potential of preclinical research. Sci. Transl. Med. 8, 320ps1 (2016).
26. S. Kathiresan, Developing medicines that mimic the natural successes of the human genome: Lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J. Am. Coll. Cardiol. 65, 1562-1566 (2015).
27. www.nih.gov/precision-medicine-initiative-cohort-program.
28. P. M. Barrett, A. Alagely, E. J. Topol, Cystic fibrosis in an era of genomically guided therapy. Hum. Mol. Genet. 21, R66-R71 (2012).
29. E. J. Topol, S. R. Steinhubl, A. Torkamani, Digital medical tools and sensors. JAMA 313, 353-354 (2015).
30. A. D. Barker, C. C. Sigma, G. J. Kelloff, N. M. Hylton, D. A. Berry, L. J. Esserman, I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009).